INS and macular degeneration: Peptides, as therapeutic agents, possess many advantages, such as small size, ease of large-scale synthesis and good biocompatibility [24–26] Some of them, like insulin for the treatment of diabetes and aflibercept for the treatment of macular degeneration, are currently used in daily clinical practice [27–29].